The management of the clinical complications of antiretroviral therapy

Infectious Disease Clinics of North America

Volumn 14, Issue 4, 2000, Pages 851-878

  Stenzel, Molly S ^a   Carpenter, Charles C J ^b  

^a Vancouver Clinic   (United States)

^b BROWN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; AMPRENAVIR; ANTIRETROVIRUS AGENT; DELAVIRDINE; DIDANOSINE; EFAVIRENZ; INDINAVIR; NELFINAVIR; NEVIRAPINE; RITONAVIR; SAQUINAVIR; STAVUDINE; ZALCITABINE; ZIDOVUDINE;

ARTICLE; BONE MARROW SUPPRESSION; DRUG HYPERSENSITIVITY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERLIPIDEMIA; LACTIC ACIDOSIS; NEPHROTOXICITY; PANCREATITIS; PERIPHERAL NEUROPATHY;

EID: 0034495449     PISSN: 08915520     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0891-5520(05)70137-9     Document Type: Article

References (165)

1. Zidovudine-associated type B lactic acidosis and hepatic steatosis in an HIV-infected patient
2. Type B lactic acidosis in an AIDS patient treated with zidovudine
3. Nevirapine induced opiate withdrawal among injection drug users with HIV receiving methadone
4. Choice of lipid-lowering drugs
5. Reaching a consensus: Lipodystrophy case definition
6. Repaglinide for type 2 diabetes mellitus
7. Rosiglitazone for type 2 diabetes mellitus
8. A cross-sectional study of metabolic disorders and lipodystrophy in HIV-infected patients treated with antiretroviral combination therapy including protease inhibitors within a phase IV cohort study of PI: APROCO-ANRS EP11
9. Abnormalities of serum amylase and lipase in HIV-positive patients
10. Acute hepatitis in HIV-infected patients during ritonavir therapy
11. Indinavir nephrolithiasis in warm climates
12. Lactic acidosis and AIDS
13. Are the decreased lipolytic enzyme activities responsible for the hypertriglyceridemia in PI-treated patients?
14. Impaired glucose tolerance, beta cell function and lipid metabolism in HIV patients under treatment with protease inhibitors
15. Lipid evaluation and glucose metabolism in HIV-1 positive patients treated with protease inhibitors
16. Metabolic changes in HIV-infected patients treated with protease inhibitors
17. Acute renal failure due to indinavir crystalluria and nephrolithiasis: Report of two cases
18. Fulminant hepatitis with severe lactate acidosis in HIV-infected patients on didanosine therapy
19. Expanding the spectrum of protease-induced lipodystrophy
20. The potential impact of efavirenz on methadone maintenance
21. Paronychia and pyogenic granuloma of the great toes in patients treated with indinavir
22. Alopecia associated with indinavir therapy
23. Ingrown toenails and indinavir: Case-control study demonstrates strong relationship [681]
24. Lactic acidosis in patients receiving nucleoside reverse transcriptase inhibitors
25. Severe hepatitis in three AIDS patients treated with indinavir
26. Fatal lactic acidosis following HAART containing stavudine, lamivudine, and saquinavir
27. Adverse effects of reverse transcriptase inhibitors: Mitochondrial toxicity as common pathway
28. Variation in incidence of indinavir-associated nephrolithiasis among HIV-positive patients
29. Evaluation of protease inhibitor-associated hyperglyeemia in a university-based HIV clinic
30. Antiretroviral therapy for HIV infection in 1998: Updated recommendations of the International AIDS Society - USA Panel
31. A syndrome of peripheral lipodystrophy, hyperlipidemia and insulin resistance in patients receiving HIV protease inhibitors
32. Pathogenesis of HIV-1-protease inhibitor associated peripheral lipodystrophy hyperlipidaemia, and insulin resistance
33. Diagnosis and prediction of HIV protease inhibitor-induced lipodystrophy and impaired glucose tolerance
34. Diagnosis, prediction, and natural course of HIV-1 protease-inhibitor-associated lipodystrophy, hyperlipidaemia, and diabetes mellitus: A cohort study
35. Reversibility of protease inhibitor lipodystrophy syndrome on stopping Pls or switching to nelfinavir
36. The effects of antiretroviral protease inhibitors on serum lipids and glucose in HIV-infected patients
37. Lactic acidosis and AIDS
38. Lactic acidosis complicating the acquired immunodeficiency syndrome
39. Survival of a human immunodeficiency patient with nucleoside-induced lactic acidosis - role of haemodialysis treatment
40. No association observed between indinavir therapy for HIV/AIDS and myocardial infraction in 4 clinical trials with 2,825 subjects
41. Non-fatal nucleoside analogue-associated actic acidosis in three HIV-infected patients
42. Acute pancreatitis in human immunodeficiency virus-infected patients: A review
43. Urinary stones in HIV-1-positive patients treated with indinavir
44. Urologic complaints in relation to indinavir plasma levels in HIV-infected patients
45. Changes in body habitus and serum lipid abnormalities in HIV-positive women on highly active antiretroviral therapy
46. Effect of initiating indinavir therapy on glucose metabolism in HIV-infected patients: Results of minimal model analysis [abstract 028]. 1st International Workshop on Adverse Drug Reactions and Lipodystropy in HIV, San Diego, 1999
47. Protease inhibitor-associated hyperglycemia
48. Lipid evaluation and glucose metabolism in HIV-infected patients before and after initiation of protease inhibitor therapy
49. Effect of recombinant human growth hormone in the treatment of visceral fat accumulation in HIV infection interim analysis [abstract 006]. 1st International Workshop on Adverse Drug Reactions and Lipodystropy in HIV, San Diego, 1999
50. Summary of the second report of the National Cholesterol Education Program (NCEP) Expert Panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel 11)
51. Protease inhibitors may increase blood glucose in HIV patients
52. Hepatomegaly and steatosis in HIV-infected patients receiving nucleoside analog antiretroviral therapy
53. Riboflavin to treat nucleoside analogue-induced lactic acidosis
54. Hepatomegaly with severe steatosis in HIV-seropositive patients
55. Incidence of fat tissue abnormalities in protease inhibitor-naïve patients treated with NRTI combinations [abstract 020]. 1st International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV, San Diego, 1999
56. One year effects of switching from HIV-1 Pls to nevirapine on metabolic abnormalities [abstract 040]. 1st International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV, San Diego, 1999
57. Protease inhibitor-induced urolithiasis
58. Evaluation of urinary pH and specific gravity in the development of indinavir induced renal stones
59. Frequency of lipodystrophy and factors associated with glucose/lipid abnormalities in a cohort of 650 patients treated by protease inhibitors
60. High prevalence of impaired glucose tolerance prior to initiating protease inhibitor therapy
61. Analysis of potential risk factors associated with the development of pancreatitis in phase I patients with AIDS or AIDS-related complex receiving didanosine
62. Hypertriglyceridemia in the acquired immunodeficiency syndrome
63. Lipids, lipoproteins, triglyceride clearance and cytokines in human immunodeficiency virus infection and the acquired immunodeficiency syndrome
64. Fasting hyperinsulinemia and changes in regional body composition in human immunodeficiency virus-infected women
65. Benign symmetric lipomatosis associated with protease inhibitors
66. Recombinant human erythropoietin in the treatment of anemia associated with human immunodeficiency virus infection and zidovodine therapy: Overview of four clinical trials
67. Severe premature coronary artery disease with protease inhibitors
68. Atorvastatin and gemfibro/il for protease inhibitor-related lipid abnormalities
69. Discontinuation of protease inhibitor therapy: Reasons and risk factors
70. Increased morbidity from severe coronary heart disease in HIV patients receiving protease inhibitors
71. Association of diabetes and protease inhibitor use in a large natural history cohort of HIV women
72. NRTI-induced mitochondrial toxicity as an aetiology for fat redistribution syndrome [abstract 041]. 1st International Workshop on Adverse Drug Reactions and Lipodystropy in HIV, San Diego, 1999
73. Diabetes and hyperglycemia in patients receiving protease inhibitors
74. Do protease inhibitors increase the risk for coronary heart disease among HIV positive patients?
75. Drug therapy: Treatment of lipid disorders
76. Indinavir urolithiasis: An emerging cause of renal colic in the HIV patients
77. Crystalluria and urinary tract abnormalities associated with indinavir
78. An increase in abdominal girth on protease inhibitor therapy is associated with visceral obesity and metabolic disturbances that closely resemble syndrome X [abstract 056]. 1st International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV, San Diego, 1999
79. Fulminant hepatic failure associated with 2′,3′-dideoxyinosine
80. 2′,3′-dideoxyinosine in patients with the acquired immunodeficiency syndrome or AIDS-related complex: A phase I trial
81. Metabolic, hepatic and muscular changes during zidovudine therapy: A drug-induced mitochondrial disease?
82. Prevalence and risk factors for hyperglycemia, dyslipidermia, and coronary disease among HIV-infected patients on initial protease inhibitor therapy
83. Effect of fenofibrate on hyperlipidemia in HIV-infected patients [abstract 044]. 1st International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV, San Diego, 1999
84. HIV protease inhibitors block adipogenesis and increase lipolysis in vitro
85. Hepatic steatosis and lactic acidosis associated with stavudine treatment in an HIV patient: A case report
86. Clinical factors related to the severity of fat redistribution in the HIV Outpatient Study (HOPS) [abstract 071]. 1st International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV, San Diego, 1999
87. "Buffalo hump" in men with HIV-1 infection
88. Zidovudine: Five years later
89. Hyperlactatemia and hepatic abnormalities in ten HIV-infected patients receiving nucleoside analog combination regimens
90. Riboflavine and severe lactic acidosis
91. Lipodystrophy in patients naïve to HIV protease inhibitors
92. A new type of urinary calculus: Indinavir
93. Protease inhibitors and nucleoside analogue reverse transcriptase inhibitors interact to cause subcutaneous fat wasting in patients with HIV infection [abstract 019]. 1st International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV, San Diego, 1999
94. Indinavir-related nephrolithiasis is associated with environmental temperature
95. Reversion of lipodystrophy after switching HIV-1 protease inhibitors to nevirapine
96. Hyperbilirubinemia in patients treated with indinavir
97. Emerging complication of antiretroviral therapy: Symptomatic hyperlactatemia
98. Acute pancreatitis as a common complication of 2′,3′-dideoxyinosine therapy in the acquired immunodeficiency syndrome
99. Case report of lipodystrophy observations in patients naïve of protease inhibitor treatment, Aquitaine Cohort, 1999 [abstract 018]. 1st International Workshop on Adverse Drug Reactions and Lipodystropy in HIV, San Diego, 1999
100. Visceral abdominal-fat accumulation associated with use of indinavir
101. Neuromuscular complications of human immunodeficiency virus infection and antiretroviral therapy
102. Randomized double-blind study comparing the efficacy of gabapentin with amitriptyline on diabetic peripheral neuropathy pain
103. Lipid elevations during non-nucleoside RTl (NNRTI) therapy: A cross-sectional analysis [abstract 054]. 1st International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV, San Diego, 1999
104. Management of protease inhibitor-associated lipodystrophy by substitution with efavirenz in virologically controlled HIV-infected persons
105. Body fat redistribution in persons on non-PI-containing regimens [abstract 053]. 1st International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV, San Diego, 1999
106. Evidence of unique metabolic effects of protease inhibitors
107. HIV-associated adipose redistribution syndrome: Overweight patients report less lipodystrophy, more fat accumulation
108. Persistent parvovirus B19 related anemia of seven years' duration in an HIV-infected patient: Complete remission associated with highly active antiretroviral therapy
109. The loin pain/indinavir syndrome and urolithiasis associated with indinavir therapy
110. Massive hepatic steatosis and lactic acidosis in a patient with AIDS who was receiving zidovudine
111. Efficacy and safety of HMG-CoA reductase inhibitors (statins) for the treatment of protease inhibitor-related hyperlipidemia: A retrospective analysis
112. Indinavir nephropathy in a AIDS patient with renal insufficiency and pyuria
113. Atherogenic dyslipidemia in HIV-infected individuals treated with protease inhibitors
114. Liposuction for protease-inhibitor associated lipodystrophy
115. Frequency of urolithiasis in individuals seropositive for human immunodeficiency virus treated with indinavir is higher than previously assumed
116. Sterile leucocyturia and reversible impairment of renal function in indinavir treated patients
117. Tolerability and toxicity of protease inhibitor-containing regimens in HIV infected patients
118. Cumulative risk for developing hyperlipidemia in HIV-infected patients treated with protease inhibitors
119. A pilot study of exercise training to reduce trunk fat in adults with HIV-associated fat redistribution
120. Prospective follow-up of a PI substitution for efavirenz in patients with HIV-related lipodystrophy syndrome [abstract 068]. 1st International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV, San Diego, 1999
121. The "steatosis-lactic acidosis syndrome" in early stage HIV infection treated with HAART
122. A multi-centre, randomized, open-label, comparative trial of the clinical benefit of switching the protease inhibitor by nevirapine in HAART-experienced patients suffering lipodystrophy
123. A syndrome of lipodystrophy in patients receiving a stable nucleoside analoque therapy
124. Effects of metformin on insulin resistance and central adiposity in patients receiving effective protease inhibitor (PI) therapy
125. Hyperglycemia associated with protease inhibitor therapy
126. Increased risk of indinavir nephropathy in women
127. Severe transient neonatal lactic acidosis during prophylactic zidovudine treatment
128. Treatment of PI-induced hyperlipidemia with bezafibrate
129. Imaging characteristics of indinavir calculi
130. Acupuncture and amitriptyline for pain due to HIV-related peripheral neuropathy: A randomized trial
131. Nucleoside analogue-associated peripheral neuropathy in human immunodeficiency virus infection
132. Validation of a dyslipidemia algorithm in HIV-positive patients
133. Management of HIV-associated adipose redistribution syndrome in women with low-dose recombinant human growth hormone
134. Preclinical investigations into the mechanism by which HIV protease inhibitors may induce metabolic disorders
135. Zidovudine-induced fatal lactie acidosis and hepatic failure in patients with acquired immunodeficiency syndrome: Report of two patients and review of the literature
136. Indinavir nephropathy
137. The effect of recombinant human growth hormone on protease inhibitor-associated fat maldistribution syndrome
138. Effects of protease inhibitor use on hyperglycemia and hyperlipidemia: A five year analysis
139. Rakotoambinina: Lipodystrophic syndromes in a cohort of HIV-1-infected patients receiving HAART with a protease inhibitor [abstract 026]. 1st International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV, San Diego, 1999
140. Indinavir-associated lipodystrophy
141. The therapy of respiratory chain encephalomyopathy: A critical review of the past and current perspective
142. Peripheral insulin resistance leading to impaired glocuse tolerance in HIV-1 patients treated with protease inhibitors
143. Treatment with protease inhibitors associated with peripheral insulin resistance and impaired glucose tolerance in HIV-1-infected patients
144. ART-associated insulin resistance: Frequency, potential causes and possible therapeutic interventions [abstract 005]. 1st International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV, San Diego, 1999
145. Effects of PPAR-activator troglitazone on protease inhibitor associated peripheral insulin resistance
146. Clinical factors related to lipodytrophy severity in the HIV Outpatient Study (HOPS)
147. Description of lipodystrophy in the HIV Outpatient Study (HOPS) [abstract 014]. 1st International Workshop on Adverse Drug Reactions and Lipodystrophy in HIV, San Diego, 1999
148. Nevirapine-associated Stevens-Johnson syndrome
149. Lipid lowering therapy in patients with HIV infections
150. Anuria and acute renal failure resulting from indinavir sulfate induced nephrolithiasis
151. Combining ritonavir and indinavir decreases indinavir-associated nephrolithiasis
152. Endocrine and metabolic evaluation of human immunodeficiency virus-infected patients with evidence of protease inhibitor-associated lipodystrophy
153. Reasons for discontinuation of protease inhibitor treatment: A clinical survey